secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-10-15T21:33:31+00:00
Accession:  0001193125-26-423054
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Sangamo Chapter 11 MOR: August net loss $14.4M, cash $23.2M; Nasdaq delisting effective Oct 17
--------------------------------------------------------------------------------

- August 2026 MOR: gross income $430,190, G&A $3,679,482, interest $192,082, reorganization items $9,979,799, net loss $14,449,029; cumulative Chapter 11-period loss $29,369,386.
- Cash rose to $23,225,696 at Aug 31 from $16,906,954 at Aug 1; August receipts $10,145,433 and disbursements $3,826,691.
- Total assets $147,881,705; total liabilities $107,262,249; prepetition unsecured debt $78,651,484; postpetition debt $28,578,222; ending net worth $40,619,456.
- Sold assets outside ordinary course for $2,300,000 cash; drew $7,000,000 under replacement DIP in August; final DIP allows up to $35,000,000; FSI credit bid $250,000 of DIP obligations.
- Nasdaq filed Form 25 on Oct 7, 2026; delisting and deregistration effective Oct 17, 2026; stock was suspended May 5, 2026 and trades OTC Pink Limited as SGMOQ.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526423054/0001193125-26-423054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526423054/d453907d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-423054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer